INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Feb 11, 2014
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director
Transactions
- Sale
Common Stock
2014-02-10$354.52/sh−368$130,463→ 1,640 total - Exercise/Conversion
Common Stock
2014-02-09+368→ 2,008 total - Exercise/Conversion
Restricted Stock Units
2014-02-09−368→ 735 total→ Common stock (368 underlying)
Holdings
- 5,938,890(indirect: See Footnote)
Common Stock
Footnotes (4)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 18, 2013.
- [F2]Each restricted stock unit("RSU") represents the contingent right to receive one share of common stock upon vesting of the unit.
- [F3]On November 16, 2012, the reporting person was granted 2,942 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 12.5% of the shares underlying the RSUs, became vested on February 9, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan(the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on every subsequent three-month anniversary of such date through August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan.
- [F4]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.